Cargando…
High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis
Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). M...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055887/ https://www.ncbi.nlm.nih.gov/pubmed/36986479 http://dx.doi.org/10.3390/ph16030379 |
_version_ | 1785015986457411584 |
---|---|
author | Moon, Dong-Hyuk Kim, Aran Song, Byung-Wook Kim, Yun-Kyung Kim, Geun-Tae Ahn, Eun-Young So, Min-Wook Lee, Seung-Geun |
author_facet | Moon, Dong-Hyuk Kim, Aran Song, Byung-Wook Kim, Yun-Kyung Kim, Geun-Tae Ahn, Eun-Young So, Min-Wook Lee, Seung-Geun |
author_sort | Moon, Dong-Hyuk |
collection | PubMed |
description | Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). Methods: This retrospective cohort study investigated 279 AS patients who were newly initiated on TNF-α blockers between April 2004 and October 2019 and 171 sex- and age-matched healthy controls. Response to TNF-α blockers was defined as a reduction in the Bath AS Disease Activity Index of ≥50% or 20 mm, and persistence referred to the time interval from the initiation to discontinuation of TNF-α blockers. Results: Patients with AS had significantly increased NLR, MLR, and PLR ratios as compared to controls. The frequency of non-response at 3 months was 3.7%, and TNF-α blockers’ discontinuation occurred in 113 (40.5%) patients during the follow-up period. A high baseline NLR but not high baseline MLR and PLR showed an independently significant association with a higher risk of non-response at 3 months (OR = 12.3, p = 0.025) and non-persistence with TNF-α blockers (HR = 1.66, p = 0.01). Conclusions: NLR may be a potential marker for predicting the clinical response and persistence of TNF-α blockers in AS patients. |
format | Online Article Text |
id | pubmed-10055887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100558872023-03-30 High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis Moon, Dong-Hyuk Kim, Aran Song, Byung-Wook Kim, Yun-Kyung Kim, Geun-Tae Ahn, Eun-Young So, Min-Wook Lee, Seung-Geun Pharmaceuticals (Basel) Article Background: This study explores the association of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) ratios with the 3-month treatment response and persistence of tumor necrosis factor-alpha (TNF-α) blockers in patients with ankylosing spondylitis (AS). Methods: This retrospective cohort study investigated 279 AS patients who were newly initiated on TNF-α blockers between April 2004 and October 2019 and 171 sex- and age-matched healthy controls. Response to TNF-α blockers was defined as a reduction in the Bath AS Disease Activity Index of ≥50% or 20 mm, and persistence referred to the time interval from the initiation to discontinuation of TNF-α blockers. Results: Patients with AS had significantly increased NLR, MLR, and PLR ratios as compared to controls. The frequency of non-response at 3 months was 3.7%, and TNF-α blockers’ discontinuation occurred in 113 (40.5%) patients during the follow-up period. A high baseline NLR but not high baseline MLR and PLR showed an independently significant association with a higher risk of non-response at 3 months (OR = 12.3, p = 0.025) and non-persistence with TNF-α blockers (HR = 1.66, p = 0.01). Conclusions: NLR may be a potential marker for predicting the clinical response and persistence of TNF-α blockers in AS patients. MDPI 2023-03-01 /pmc/articles/PMC10055887/ /pubmed/36986479 http://dx.doi.org/10.3390/ph16030379 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Moon, Dong-Hyuk Kim, Aran Song, Byung-Wook Kim, Yun-Kyung Kim, Geun-Tae Ahn, Eun-Young So, Min-Wook Lee, Seung-Geun High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
title | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
title_full | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
title_fullStr | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
title_full_unstemmed | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
title_short | High Baseline Neutrophil-to-Lymphocyte Ratio Could Serve as a Biomarker for Tumor Necrosis Factor-Alpha Blockers and Their Discontinuation in Patients with Ankylosing Spondylitis |
title_sort | high baseline neutrophil-to-lymphocyte ratio could serve as a biomarker for tumor necrosis factor-alpha blockers and their discontinuation in patients with ankylosing spondylitis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055887/ https://www.ncbi.nlm.nih.gov/pubmed/36986479 http://dx.doi.org/10.3390/ph16030379 |
work_keys_str_mv | AT moondonghyuk highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT kimaran highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT songbyungwook highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT kimyunkyung highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT kimgeuntae highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT ahneunyoung highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT sominwook highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis AT leeseunggeun highbaselineneutrophiltolymphocyteratiocouldserveasabiomarkerfortumornecrosisfactoralphablockersandtheirdiscontinuationinpatientswithankylosingspondylitis |